PMID- 30675213 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 17 IP - 2 DP - 2019 Feb TI - Expression of p53 in ground-glass nodule of lung cancer and non-lung cancer patients. PG - 1559-1564 LID - 10.3892/ol.2018.9797 [doi] AB - The present study investigated the expression of p53 in ground-glass nodule (GGN) of lung cancer and non-lung cancer patients, and explored the correlation with prognosis. A total of 120 GGN patients admitted to the Department of Respiratory Medicine in the Second Affiliated Hospital of Zhejiang University School of Medicine during the period from March 2010 to March 2014 were selected. These patients included 60 lung cancer patients and 60 non-tumor patients. Biopsy or surgical specimens were collected. Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) were used to detect p53 gene and protein expression in the two groups of GGN tissues. All patients were followed up for 3 years and the relationship between p53 protein expression and the overall survival (OS) of the two groups of patients was analyzed. In GGN cells of non-cancer patients, p53 absence was observed in 6 cases and the absence rate was 10.0%. In GGN cells of cancer patients, the absence rate was significantly higher than that of non-cancer GGN group (p<0.05). The positive rate of p53-positive cases in non-tumor patients GGN group was lower than that of in GGN tissues of lung cancer patients (p<0.05). There were no deaths in the GGN non-cancer group (n=60) within 3 years, while 43 deaths occurred in GGN lung cancer group. The median survival time and the 3-year survival rate of patients with p53 positive was lower than that of p53-negative patients (p<0.05). p53 was overexpressed in GGN of lung cancer patients, and p53 overexpression is significantly correlated with poor prognosis of lung cancer patients. p53 plays an important role in transformation from GGN to lung cancer. Detection of p53 expression in GGN tissue may provide guidance for the diagnosis and prognosis of lung cancer. FAU - Teng, Zhihua AU - Teng Z AD - Department of Thoracic Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China. FAU - Chen, Wen AU - Chen W AD - Department of TCM, The Second Affiliated Hospital of Fujian Medical University, Respiratory Medicine Center of Fujian Province, Quanzhou, Fujian 362000, P.R. China. FAU - Yang, Dongyong AU - Yang D AD - Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Fujian Medical University, Respiratory Medicine Center of Fujian Province, Quanzhou, Fujian 362000, P.R. China. FAU - Zhang, Zhenghua AU - Zhang Z AD - Department of Oncology, Jingan District Central Hospital, Shanghai 200040, P.R. China. FAU - Zhu, Lifei AU - Zhu L AD - Center of Cancer, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai 201620, P.R. China. FAU - Wu, Fubing AU - Wu F AD - Department of Medical Oncology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China. LA - eng PT - Journal Article DEP - 20181205 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC6341667 OTO - NOTNLM OT - ground-glass nodule OT - lung cancer OT - p53 OT - prognosis EDAT- 2019/01/25 06:00 MHDA- 2019/01/25 06:01 PMCR- 2018/12/05 CRDT- 2019/01/25 06:00 PHST- 2018/05/19 00:00 [received] PHST- 2018/11/16 00:00 [accepted] PHST- 2019/01/25 06:00 [entrez] PHST- 2019/01/25 06:00 [pubmed] PHST- 2019/01/25 06:01 [medline] PHST- 2018/12/05 00:00 [pmc-release] AID - OL-0-0-9797 [pii] AID - 10.3892/ol.2018.9797 [doi] PST - ppublish SO - Oncol Lett. 2019 Feb;17(2):1559-1564. doi: 10.3892/ol.2018.9797. Epub 2018 Dec 5.